PE20080369A1 - CYANOPYRIDINES SUBSTITUTED AS PROTEIN KINASE INHIBITORS - Google Patents
CYANOPYRIDINES SUBSTITUTED AS PROTEIN KINASE INHIBITORSInfo
- Publication number
- PE20080369A1 PE20080369A1 PE2007000747A PE2007000747A PE20080369A1 PE 20080369 A1 PE20080369 A1 PE 20080369A1 PE 2007000747 A PE2007000747 A PE 2007000747A PE 2007000747 A PE2007000747 A PE 2007000747A PE 20080369 A1 PE20080369 A1 PE 20080369A1
- Authority
- PE
- Peru
- Prior art keywords
- nicotinonitrile
- cyanopyridines
- substituted
- protein kinase
- kinase inhibitors
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical class N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 abstract 1
- -1 3-CHLOROPHENYL Chemical class 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
REFERIDA A UN DERIVADO DE CIANOPIRIDINA DE FORMULAS (I) O (I'), DONDE X ES NR3-Y, O-Y, C(O)O-Y, S(O)m-Y, ENTRE OTROS; Y ES ALQUILO C1-C10, ALQUENILO C2-C10, HALOALQUILO C1-C10, ENTRE OTROS; R1 ES FENILO OPCIONALMENTE SUSTITUIDO CON UNO A CUATRO GRUPOS -Y-R4; R2 ES ARILO C6-C14 O UN HETEROARILO DE 5 A 14 MIEMBROS, OPCIONALMENTE SUSTITUIDOS CON -Y-R4 U -O-Y-R4; R4 ES HALOGENO, CN, NO2, UN GRUPO OXO, ENTRE OTROS; m ES 0, 1 O 2. SON COMPUESTOS PREFERIDOS: 4-[(3-CLOROFENIL)AMINO]-5-(3,4-DIMETOXIFENIL)NICOTINONITRILO, 5-(3,4-DIMETOXIFENIL)-4-[(3-FLUORFENIL)AMINO]NICOTINONITRILO, 4-ANILINO-5-(3,4-DIMETOXIFENIL)NICOTINONITRILO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE PROTEINA QUINASAS Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNESREFERRING TO A CYANOPYRIDINE DERIVATIVE OF FORMULAS (I) O (I '), WHERE X IS NR3-Y, O-Y, C (O) O-Y, S (O) m-Y, AMONG OTHERS; AND IT IS C1-C10 ALKYL, C2-C10 ALKENYL, C1-C10 HALOALKYL, AMONG OTHERS; R1 IS OPTIONALLY SUBSTITUTE PHENYL WITH ONE TO FOUR GROUPS-AND-R4; R2 IS C6-C14 ARYL OR A 5 TO 14-MEMBER HETEROARYL, OPTIONALLY REPLACED WITH -Y-R4 OR -O-Y-R4; R4 IS HALOGEN, CN, NO2, AN OXO GROUP, AMONG OTHERS; m IS 0, 1 OR 2. PREFERRED COMPOUNDS ARE: 4 - [(3-CHLOROPHENYL) AMINO] -5- (3,4-DIMETOXIPHENIL) NICOTINONITRILE, 5- (3,4-DIMETOXIFENIL) -4 - [(3- FLUORPHENIL) AMINO] NICOTINONITRILE, 4-ANILINO-5- (3,4-DIMETOXIFENIL) NICOTINONITRILE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE INHIBITORS OF PROTEIN KINASES AND ARE USEFUL IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81318206P | 2006-06-13 | 2006-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080369A1 true PE20080369A1 (en) | 2008-06-04 |
Family
ID=38832510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000747A PE20080369A1 (en) | 2006-06-13 | 2007-06-13 | CYANOPYRIDINES SUBSTITUTED AS PROTEIN KINASE INHIBITORS |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2027093A2 (en) |
| JP (1) | JP2009539993A (en) |
| CN (1) | CN101454287A (en) |
| AR (1) | AR061367A1 (en) |
| AU (1) | AU2007258352A1 (en) |
| BR (1) | BRPI0712776A2 (en) |
| CA (1) | CA2650666A1 (en) |
| CL (1) | CL2007001738A1 (en) |
| MX (1) | MX2008015805A (en) |
| PE (1) | PE20080369A1 (en) |
| TW (1) | TW200815356A (en) |
| WO (1) | WO2007146323A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8569337B2 (en) | 2008-07-23 | 2013-10-29 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| AU2009279611A1 (en) * | 2008-08-06 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Aminopyridine kinase inhibitors |
| CN103408489A (en) * | 2013-08-29 | 2013-11-27 | 武穴市永宁医药化工有限公司 | Preparation method of 3-cyanopyridine oxynitride |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0215823D0 (en) * | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
| MXPA05006367A (en) * | 2002-12-12 | 2005-08-29 | Pharmacia Corp | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors. |
| CN101223143A (en) * | 2005-05-18 | 2008-07-16 | 惠氏公司 | 3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same |
| CL2007001737A1 (en) * | 2006-06-13 | 2008-01-25 | Wyeth Corp | Compounds derived from cyanopyridines; protein kinase inhibitors; pharmaceutical composition; and use for the treatment or inhibition of a protein kinase mediated disorder, such as autoimmune and inflammatory disease. |
-
2007
- 2007-06-13 PE PE2007000747A patent/PE20080369A1/en not_active Application Discontinuation
- 2007-06-13 AU AU2007258352A patent/AU2007258352A1/en not_active Abandoned
- 2007-06-13 EP EP07796050A patent/EP2027093A2/en not_active Withdrawn
- 2007-06-13 BR BRPI0712776-6A patent/BRPI0712776A2/en not_active IP Right Cessation
- 2007-06-13 MX MX2008015805A patent/MX2008015805A/en unknown
- 2007-06-13 JP JP2009515470A patent/JP2009539993A/en not_active Withdrawn
- 2007-06-13 CA CA002650666A patent/CA2650666A1/en not_active Abandoned
- 2007-06-13 TW TW096121315A patent/TW200815356A/en unknown
- 2007-06-13 AR ARP070102592A patent/AR061367A1/en not_active Application Discontinuation
- 2007-06-13 WO PCT/US2007/013851 patent/WO2007146323A2/en not_active Ceased
- 2007-06-13 CL CL2007001738A patent/CL2007001738A1/en unknown
- 2007-06-13 CN CNA2007800190593A patent/CN101454287A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0712776A2 (en) | 2013-12-17 |
| EP2027093A2 (en) | 2009-02-25 |
| WO2007146323A3 (en) | 2008-04-17 |
| AR061367A1 (en) | 2008-08-20 |
| CA2650666A1 (en) | 2007-12-21 |
| TW200815356A (en) | 2008-04-01 |
| WO2007146323A2 (en) | 2007-12-21 |
| AU2007258352A1 (en) | 2007-12-21 |
| JP2009539993A (en) | 2009-11-19 |
| CL2007001738A1 (en) | 2008-01-18 |
| CN101454287A (en) | 2009-06-10 |
| MX2008015805A (en) | 2009-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090714A1 (en) | IMIDAZOPYRIDAZINES AND PYROLO-PYRIMIDINES SUBSTITUTED AS LIPID KINASE INHIBITORS | |
| PE20120252A1 (en) | HETEROARYL-ARYL-UREAS COMPOUNDS AS KINASE INHIBITORS | |
| PE20090717A1 (en) | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | |
| ATE406351T1 (en) | CONDENSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | |
| PE20090617A1 (en) | AMINO-5 - [- 4- (DIFLUOROMETOXI) PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF -SECRETASE | |
| ECSP105253A (en) | DERIVATIVES OF 5-PHENYLTIAZOL AND USE AS INHIBITORS OF PI3 CINASA | |
| EA200802203A1 (en) | DIQUETOPYPERSON AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | |
| MX2009011964A (en) | Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof. | |
| EA200602062A1 (en) | AMIDOCONOMINATION AND THEIR APPLICATION AS PHARMACEUTICAL FACILITIES | |
| BRPI0815715A8 (en) | 5-(-4-(HALOALKOXY)PHENYL)PYRIMIDINE-2-AMINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS. | |
| ATE457311T1 (en) | AMINOPYRIDINES AND AMINOPYRIMIDINES SUITABLE AS INHIBITORS OF PROTEIN KINASES | |
| PE20061436A1 (en) | DERIVATIVES OF AMIDE SUBSTITUTED AS PROTEIN KINASE INHIBITORS | |
| PE20090160A1 (en) | AMINO-5- [4- (DIFLUOROMETOXI) SUBSTITUTE PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS | |
| PE20080890A1 (en) | DERIVATIVES OF IMIDAZOLONE AND IMIDAZOLIDINONE AS INHIBITORS OF 11b-HSD1 FOR DIABETES | |
| PE20091201A1 (en) | AMIDES SUBSTITUTED AS INHIBITORS OF BRUTON TYROSINE KINASE (Btk) | |
| PE20080677A1 (en) | PYRROLOTRIAZINE INHIBITORS CINAZA | |
| PE20090237A1 (en) | SULFONAMID DERIVATIVES AS SODIUM CHANNELS INHIBITORS | |
| AR087355A1 (en) | DERIVATIVES OF PIRIDIN-2 (1H) -ONA AS JAK INHIBITORS | |
| HRP20090340T1 (en) | 5-PHENYL-4-METHYL-THIAZOL-2-IL-AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3) ENZYME INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE AIRWAYS | |
| PE20170695A1 (en) | INDOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINE INHIBITORS | |
| EA201170090A1 (en) | PIRAZOLOCHINAZOLINS | |
| ATE489088T1 (en) | N-(PHENYLMETHYL)-2-(1H-PYRAZOLE-4-YL) ACETAMIDE DERIVATIVES AS P2X7 ANTAGONISTS FOR THE TREATMENT OF PAIN, INFLAMMATION AND NEURODEGENERATION | |
| PE20080209A1 (en) | GLYCINE DERIVATIVES AS PROLYL HYDROXYLASE INHIBITORS | |
| PE20080828A1 (en) | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASE | |
| CR20110261A (en) | PIRAZOLO COMPOUNDS [1,5-a] PYRIMIDINE REPLACED AS TRK CINASA IHNIBIDORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |